| 1 |
31697031 | Sjogren-Larsson syndrome associated hypermelanosis. | 2020 Apr |
1 |
| 2 |
32021380 | Sjogren-Larsson Syndrome: Mechanisms and Management. | 2020 |
1 |
| 3 |
32506993 | Macular crystalline inclusions in Sjögren-Larsson syndrome are dynamic structures that undergo remodeling. | 2020 Aug |
1 |
| 4 |
31273323 | Phenotypic and mutational spectrum of thirty-five patients with Sjögren-Larsson syndrome: identification of eleven novel ALDH3A2 mutations and founder effects. | 2019 Sep |
2 |
| 5 |
28543186 | Clinical, biochemical, and genetic aspects of Sjögren-Larsson syndrome. | 2018 Apr |
2 |
| 6 |
27012748 | Hormetic and regulatory effects of lipid peroxidation mediators in pancreatic beta cells. | 2016 Jun |
1 |
| 7 |
27547594 | Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome. | 2016 Apr |
3 |
| 8 |
25344796 | N-acyl-ω-aminoaldehydes are efficient substrates of plant aminoaldehyde dehydrogenases. | 2015 Jan |
1 |
| 9 |
25432520 | Plasmalogens and fatty alcohols in rhizomelic chondrodysplasia punctata and Sjögren-Larsson syndrome. | 2015 Jan |
2 |
| 10 |
24036493 | Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function. | 2014 Mar |
3 |
| 11 |
21187079 | Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. | 2011 May 30 |
1 |
| 12 |
19965611 | Monitoring of fatty aldehyde dehydrogenase by formation of pyrenedecanoic acid from pyrenedecanal. | 2010 Jun |
1 |
| 13 |
18174527 | FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes. | 2008 May |
1 |
| 14 |
18035827 | Characterisation of recombinant human fatty aldehyde dehydrogenase: implications for Sjögren-Larsson syndrome. | 2007 Oct |
1 |
| 15 |
16525484 | Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren-Larsson syndrome. | 2006 Jul |
1 |
| 16 |
15834613 | Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjogren-Larsson syndrome. | 2005 Jun |
4 |